Tin-117m, the active ingredient in Synovetin OA, has been shown to slow OA progression in rodent models

Synovetin OA

Preclinical and rodent studies demonstrate disease
modification properties1,2

Tin-117m was shown to:1,2

  • Substantially reduce synovitis in rodent models
  • Significantly slow bony remodeling

“Histopathology indicates a disease modifying positive therapeutic effect in rodent models.”

—Dr. Alison Bendele, Senior Pathologist, DVM, PhD, DACVP
President & CEO, Inotiv, Inc. and study author

References:
1. Doerr C, Bendele A, Simon J, et al. Poster presented at the Society of Nuclear Medicine & Molecular Imaging Annual Conference. San Diego, CA. 2016.
2. Data on File. Pathology Report. Inotiv, Inc.; Boulder, CO.

Sign up to receive a link to the paper

Evidence of osteoarthritis disease modification with a Sn-117m microparticle device: a review and validation in mammalian Models” when published in peer-reviewed Frontiers in Veterinary Science.


    keyboard_arrow_up

    Important Information About Synovetin OA®

    Studied in canine elbows, Synovetin OA is given by authorized veterinarians. Temporary discomfort in treated joints may occur. Talk to a treating veterinarian near you for more information including what to expect following treatment and visit activedognow.com.